The Immunotherapy Foundation icon, an "if" inside a circle A blue and green "stop" X A DNA symbol in a ring An injection in a ring A pill in a ring A green and blue broken chain link A location icon A dark location icon A telephone icon A dark phone icon An email/letter icon A dark mail icon Facebook icon Facebook icon Twitter icon Twitter icon Instagram icon Instagram icon A hamburger menu A closing X icon A simple caret A systemic icon Bullseye A clock Reduced side-effects Resistance

Making Progress, Every Day.

Keep up with the latest trials and treatments

News & Updates Patient Resources Go T Cells Go!

All Trials & Treatments

Vulvar Cancer

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Trial Identifier: NCT03192943
Sponsors: Bristol-Myers Squibb
Date: 6/2017 (last updated 6/2017)
Regions: Multi-region; Japan, Local Institution, Chuo-ku, Tokyo, 1040045. Other recruiting sites have contact information. Please contact the sites directly by emailing: Clinical.Trials@bms.com. First line of the email MUST contain NCT # and Site #.

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

https://clinicaltrials.gov/show/NCT03192943


A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03192345
Sponsors: Sanofi
Date: 6/2017 (last updated 6/2017)
Regions: US; South; Mary Crowley Cancer Research, Dallas, Texas, 75230; Contact: 800-633-1610 ext 1 then # Contact-US@sanofi.com

To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.

https://clinicaltrials.gov/show/NCT03192345


A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Trial Identifier: NCT03203876
Sponsors: Bristol-Myers Squibb, Ono Pharmaceuticals
Date: 6/2017 (last updated 6/2017)
Regions: Asia; Japan; Local Institution, Kashiwa-shi, Chiba, 2778577 (Site 0001); Local Institution, Kobe, Hyogo, 6500017 (Site 0002). Contact: Clinical.Trials@bms.com - First line of the email MUST contain NCT # and Site #

The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors.

https://clinicaltrials.gov/show/NCT03203876


The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors

Trial Identifier: NCT03182673
Sponsors: Jiangsu HengRui Medicine Co., Ltd.
Date: 6/2017 (last updated 6/2017)
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060 - Contact: RuiHua Xu, MD, PhD 86-20-8734-3008 xurh@sysucc.org.cn or Yi Liu, PhD 86-21-6045-3192 ext 822 liuy@shhrp.com.

This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity(DLT)and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.

https://clinicaltrials.gov/show/NCT03182673


Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

Trial Identifier: NCT03179436
Sponsors: Merck Sharp & Dohme Corp.
Date: 5/2017 (last updated 6/2017)
Regions: Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com. Please refer to this study by its ClinicalTrials.gov identifier: NCT03179436.

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.

https://clinicaltrials.gov/show/NCT03179436


Special Combination of OBP-301 and Pembrolizumab

Trial Identifier: NNCT03172819
Sponsors: Toshihiko Doi, National Cancer Center Hospital East; Oncolys BioPharma Inc, Merck Sharp & Dohme Corp.
Date: 5/2017 (last updated 6/2017)
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba. Contact: Takashi Kojima, Dr +81-4-7133-1111 ext 91266 OBPem_core@east.ncc.go.jp

This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.

https://clinicaltrials.gov/show/NCT03172819


Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Identifier: NCT03172936
Sponsors: Novartis
Date: 5/2017 (last updated 5/2017)
Regions: Contact: Novartis Pharmaceuticals 1-888-669-6682 Novartis.email@novartis.com. Please refer to this study by its ClinicalTrials.gov identifier: NCT03172936

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

https://clinicaltrials.gov/show/NCT03172936


Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Trial Identifier: NCT02834013
Sponsors: National Cancer Institute (NCI)
Date: 7/2016 (last updated 4/2017)
Regions: Multi-region; See all 555 study sites here

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

https://clinicaltrials.gov/ct2/show/NCT02834013?term=%22vulvar+cancer%22&recr=Open&rank=14


Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Trial Identifier: NCT02628067
Sponsors: Merck Sharp & Dohme Corp.
Date: 12/2015 (last updated 2/2017)
Regions: Multi-region; See all 42 study locations

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

https://clinicaltrials.gov/ct2/show/NCT02628067?term=vulvar+cancer&recr=Open&rank=49


Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Trial Identifier: NCT03190811
Sponsors: Capital Medical Unviersity, Duke University
Date: 6/2015 (last updated 6/2017)
Regions: Asia; China; Beijing - Capital Medical University Cancer Center/Beijing Shijitan Hospital Recruiting Beijing, Beijing, China, 100038 Contact: Jun Ren, MD, PhD 86-10-63926317 renjun9688@yahoo.com

The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.Furthermore,to characterize response to therapy we intent to evaluate the role of cell-free DNA (cfDNA) and immune repertoire based on the next generation sequencing.

https://clinicaltrials.gov/ct2/show/NCT03190811


Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia (PITVIN)

Trial Identifier: NCT00005095
Sponsors: Medical University of Graz Collaborator: Austrian Science Fund (FWF)
Date: 5/2013 (last updated 8/2016)
Regions: Western Europe; EU; Austria

To evaluate the efficacy (defined as complete clinical response at 6 months) of imiquimod vs. standard treatment (surgery) for vulvar intraepithelial neoplasia (VIN).

https://clinicaltrials.gov/ct2/show/NCT01861535?term=%22vulvar%22+%22cancer%22&recr=Open&rank=9



Vulvar Cancer (HPV+)

E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers

Trial Identifier: NCT02858310
Sponsors: National Cancer Institute (NCI)
Date: 8/2016 (last updated 4/2017)
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center (Bethesda, Maryland)

Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.

https://clinicaltrials.gov/ct2/show/study/NCT02858310?term=%22vulvar+cancer%22&recr=Open&rank=9#contacts


An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)

Trial Identifier: NCT02488759
Sponsors: Bristol-Myers Squibb
Date: 6/2015 (last updated 4/2017)
Regions: Multi-region; Recruiting sites have contact information. Please contact the sites directly: clinical.trials@bms.com; Contact: First line of the email MUST contain NCT# and Site #

The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the types of tumors identified.

https://clinicaltrials.gov/ct2/show/NCT02488759?term=%22vulvar+cancer%22&recr=Open&rank=6


HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA

Trial Identifier: NCT02379520
Sponsors: Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System
Date: 2/2015 (last updated 2/2017)
Regions: US; South; Houston Methodist Hospital, Houston, Texas

The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV associated cancers. If the treatment with HPVST cells alone proves safe (Group A), additional group of patients (Group B) will receive Nivolumab in addition to HPVST cells in a lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma. Lymphodepletion will decrease the level of circulating T cells prior to infusion of HPVST cells, thereby giving them room to expand. The purpose of this part of the study is to find out if TGF-beta resistant HPVST cells in combination with Nivolumab are safe, how long they last in the body and if they are more effective than HPVST cells alone in controlling the tumor.

https://clinicaltrials.gov/ct2/show/NCT02379520?term=%22vulvar+cancer%22&recr=Open&rank=13

 

Patient Diagram